BOSTON--(BUSINESS WIRE)--Researchers from leading academic healthcare institutions and CSA Medical, Inc. (www.CSAmedical.com), have published a manuscript in Diseases of the Esophagus titled, “Safety and Efficacy of Endoscopic Spray Cryotherapy for Barrett’s Dysplasia: Results of the National Cryospray Registry.” CSA Medical is the leading provider of advanced spray cryotherapy technology that flash freezes and destroys benign and malignant tissues inside the body.
Barrett’s dysplasia refers to precancerous changes in the cells of the esophagus. Gastroesophageal reflux disease can cause Barrett’s esophagus, a change in the normal esophageal cells to intestinal-like cells, or intestinal metaplasia. These cells can become abnormal or dysplastic and progress to low grade dysplasia (LGD) and then high grade dysplasia (HGD). HGD significantly increases a person’s risk for esophageal cancer.
Previous studies have shown the efficacy of endoscopic spray cryotherapy in ablating HGD in Barrett’s esophagus, however they were retrospective in design. The aim of this study was to prospectively assess the efficacy and safety of spray cryotherapy in patients with LGD or HGD. Data from the largest prospective cohort to date demonstrates that spray cryotherapy is a safe and effective device for ablation of Barrett’s esophagus with low or high grade dysplasia.
“This study on endoscopic spray cryotherapy is an exciting and important addition to our knowledge of the management of dysplastic Barrett’s mucosa,” said Walter Coyle, MD, Gastroenterology Division Head at Scripps Clinic Torrey Pines and senior author on the paper. “The study shows that spray cryotherapy with low pressure liquid nitrogen is very safe and comfortable for patients and is effective for ablation of the abnormal esophageal lining. Spray cryotherapy is highly effective for short to medium length Barrett’s esophagus with low or high grade dysplasia.”
About the Study
Researchers at six centers located across
the U.S. enrolled patients with dysplastic Barrett’s esophagus in a
prospective registry. Ninety-six patients with Barrett’s dysplasia
underwent 321 spray cryotherapy procedures, with an average of 3.3 per
patient. Spray cryotherapy was performed every two to three months until
there was no endoscopic evidence of Barrett’s esophagus and no
histological evidence of dysplasia. Surveillance endoscopies were
conducted for up to two years. Primary outcome measures were complete
eradication of dysplasia and complete eradication of all intestinal
metaplasia. Participating centers include:
- Scripps Clinic, La Jolla, CA
- University of Maryland School of Medicine and Greenebaum Cancer Center, Baltimore, MD
- Cleveland Clinic, Cleveland, OH
- North Shore Long Island Jewish Health System and ProHEALTHcare Associates, Syosset and Lake Success, NY
- University of North Carolina School of Medicine, Chapel Hill, NC
- Alpert School of Medicine of Brown University, Providence, RI
Access to the full manuscript of the study is available online at http://onlinelibrary.wiley.com/doi/10.1111/dote.12330/abstract
About CSA Medical
CSA Medical, Inc. develops and
manufactures a proprietary interventional spray cryotherapy technology
platform comprised of a device and specialty catheters that enable
delivery of spray cryogen inside the body to flash freeze and destroy
unwanted tissue. The Company is the first to harness the power of low
pressure, extremely cold (-196 o C) liquid nitrogen spray
inside the body. The truFreeze® System is intended for cryogenic
destruction of tissue requiring either active or passive venting during
surgical procedures. The truFreeze® System is indicated for use as a
cryosurgical tool in the fields of dermatology, gynecology, and general
surgery, to ablate benign and malignant lesions. To learn more, please
visit www.csamedical.com.
